Genomic prognostic markers in hepatocellular carcinoma;Pronóstico genómico en el carcinoma hepatocelular

Gastroenterologia y Hepatologia

Volumn 35, Issue 2, 2012, Pages 94-101

  Alsinet, Clara ^a,b   Villanueva, Augusto ^a,c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Biomarker; Gene signature; Liver cancer; REMARK

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; PARAFFIN; TRANSCRIPTOME;

ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; GENE IDENTIFICATION; HIGH RISK PATIENT; HIGH THROUGHPUT SCREENING; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MARKER GENE; PREOPERATIVE EVALUATION; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; GENOMICS; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 84856967492     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2011.10.003     Document Type: Article

References (65)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. Cancer Statistics, 2009. CA: A Cancer Journal for Clinicians 2009, 59:225.
2. Altekruse S.F., Mcglynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491.
3. Elserag H., Rudolph K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
4. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
5. Forner A., Ayuso C., Isabel Real M., Sastre J., Robles R., Sangro B., et al. Diagnosis and treatment of hepatocellular carcinoma. Med Clin 2009, 132:272-287.
6. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
7. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J-F Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
8. Villanueva A., Llovet J.M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011, 140:1410-1426.
9. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
10. Forner A., Reig M.E., Rodriguez de Lope C., Bruix J. Current strategy for staging and treatment: The BCLC Update and Future Prospects. Semin Liver Dis 2010, 30:61-74.
11. Marrero J.A., Fontana R.J., Barrat A., Askari F., Conjeevaram H.S., Su G.L., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-716.
12. Guías de práctica clínica [Internet] [consultado 28 Sep 2011]. Disponible en: http://portal.guiasalud.es/.
13. Llovet J.M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25:181-200.
14. Imamura H., Matsuyama Y., Tanaka E., Ohkubo T., Hasegawa K., Miyagawa S., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-207.
15. Adachi E., Maeda T., Matsumata T., Shirabe K., Kinukawa N., Sugimachi K., et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995, 108:768-775.
16. Kumada T., Nakano S., Takeda I., Sugiyama K., Osada T., Kiriyama S., et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997, 25:87-92.
17. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
18. Ercolani G., Grazi G.L., Ravaioli M., Del Gaudio M., Gardini A., Cescon M., et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003, 237:536-543.
19. Cucchetti A., Vivarelli M., Piscaglia F., Nardo B., Montalti R., Grazi G.L., et al. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 2005, 43:310-316.
20. Portolani N., Coniglio A., Ghidoni S., Giovanelli M., Benetti A., Tiberio G.A.M., et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006, 243:229-235.
21. Wu J.-C., Huang Y.-H., Chau G.-Y., Su C.-W., Lai C.-R., Lee P.-C., et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009, 51:890-897.
22. Ishizawa T., Hasegawa K., Aoki T., Takahashi M., Inoue Y., Sano K., et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008, 134:1908-1916.
23. Minguez B., Hoshida Y., Villanueva A., Toffanin S., Cabellos L., Thung S., et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011, 55:1325-1331.
24. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
25. Yao F. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
26. Mazzaferro V., Llovet J.M., Miceli R., Schiavo M., Mariani L., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
27. Salem R., Lewandowski R.J., Mulcahy M.F., Riaz A., Ryu R.K., Ibrahim S., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138:52-64.
28. Subramanian J., Simon R. What should physicians look for in evaluating prognostic gene-expression signatures?. Nature Publishing Group 2010, 7:327-334.
29. Ye Q.-H., Qin L.-X., Forgues M., He P., Kim J.W., Peng A.C., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003, 9:416-423.
30. Budhu A., Forgues M., Ye Q., Jia H., He P., Zanetti K., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10:99-111.
31. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359:1995-2004.
32. Villanueva A., Hoshida Y., Battiston C., Tovar V., Sia D., Alsinet C., et al. Combining Clinical Pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011, 140:1501-1512. e2.
33. Boyault S., Rickman D.S., De Reyniès A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2006, 45:42-52.
34. Yamashita T., Forgues M., Wang W., Kim J.W., Ye Q., Jia H., et al. EpCAM and -fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008, 68:1451-1461.
35. Lee J.-S., Heo J., Libbrecht L., Chu I.-S., Kaposi-Novak P., Calvisi D.F., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006, 12:410-416.
36. Budhu A., Jia H.-L., Forgues M., Liu C.-G., Goldstein D., Lam A., et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47:897-907.
37. Jiang J., Gusev Y., Aderca I., Mettler T.A., Nagorney D.M., Brackett D.J., et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008, 14:419-427.
38. Calvisi D.F., Ladu S., Gorden A., Farina M., Lee J.-S., Conner E.A., et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007, 117:2713-2722.
39. Lin C.H., Hsieh S.Y., Sheen I.S., Lee W.C., Chen T.C., Shyu W.C., et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001, 61:4238-4243.
40. Gao W., Kondo Y., Shen L., Shimizu Y., Sano T., Yamao K., et al. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 2008, 29:1901-1910.
41. Ji J., Shi J., Budhu A., Yu Z., Forgues M., Roessler S., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009, 361:1437-1447.
42. Coulouarn C., Factor V.M., Andersen J.B., Durkin M.E., Thorgeirsson S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28:3526-3536.
43. Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., Toffanin S., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009, 41:843.
44. Li W., Xie L., He X., Li J., Tu K., Wei L., et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008, 123:1616-1622.
45. Gramantieri L., Fornari F., Ferracin M., Veronese A., Sabbioni S., Calin G.A., et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009, 15:5073-5081.
46. Murakami Y., Yasuda T., Saigo K., Urashima T., Toyoda H., Okanoue T., et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25:2537-2545.
47. Lee S., Lee H.J., Kim J.-H., Lee H.-S., Jang J.J., Kang G.H. Aberrant F CpG island hypermethylation along multistep F hepatocarcinogenesis. Am J Pathol 2003, 163:1371-1378.
48. Kwon G.Y., Yoo B.C., Koh K.C., Cho J.W., Park W.S., Park C.K. Promoter methylation of E-cadherin in hepatocellular carcinomas and dysplastic nodules. J Korean Med Sci 2005, 20:242-247.
49. Lou C., Du Z., Yang B., Gao Y., Wang Y., Fang S. Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin. Cancer Sci 2009, 100:996-1004.
50. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
51. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008, 47:1955-1963.
52. Toffanin S., Hoshida Y., Lachenmayer A., Villanueva A., Cabellos L., Minguez B., et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011, 140:1618-1628.
53. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H-W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
54. Martinez R., Martin-Subero J.I., Rohde V., Kirsch M., Alaminos M., Fernandez A.F., et al. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009, 4:255-264.
55. Croswell J.M., Kramer B.S. Clinical trial design and evidence-based outcomes in the study of liver diseases. J Hepatol 2009, 50:817-826.
56. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184.
57. Totoki Y., Tatsuno K., Yamamoto S., Arai Y., Hosoda F., Ishikawa S., et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 2011.
58. Carpenter D., Kesselheim A.S., Joffe S. Reputation and precedent in the bevacizumab decision. N Engl J Med 2011.
59. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
60. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
61. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011.
62. Cheng A.-L., Kang Y.-K., Chen Z., Tsao C.-J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
63. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., Phase II, et al. Study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-4300.
64. Villanueva A., Newell P., Chiang D., Friedman S., Llovet J. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:55-76.
65. Villanueva A., Hoshida Y., Toffanin S., Lachenmayer A., Alsinet C., Savic R., et al. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010, 16:4688-4694.